Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

NMRA

Neumora Therapeutics Inc

Oct 31 • 04:00PM ET

3.02

+0.09 3.07 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX NBIX AXSM ACAD SAGE ALKS BHVN PRTA AVXL

| Held by: VTI VXF SCHA IBB PRFZ VHT SCHB BTEC AVSC IBBQ

Index	-	P/E	-	EPS (ttm)	-1.57	Insider Own	66.44%	Shs Outstand	161.95M	Perf Week	14.83%
Market Cap	489.08M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	5.64%	Shs Float	54.34M	Perf Month	69.66%
Enterprise Value	291.45M	PEG	-	EPS next Q	-0.33	Inst Own	22.90%	Short Float	12.49%	Perf Quarter	83.03%
Income	-252.09M	P/S	-	EPS this Y	8.44%	Inst Trans	-11.50%	Short Ratio	5.40	Perf Half Y	289.07%
Sales	0.00M	P/B	2.67	EPS next Y	27.71%	ROA	-80.25%	Short Interest	6.79M	Perf YTD	-71.51%
Book/sh	1.13	P/C	2.25	EPS next 5Y	12.12%	ROE	-89.37%	52W High	14.09 -78.57%	Perf Year	-74.25%
Cash/sh	1.34	P/FCF	-	EPS past 3/5Y	0.69% -	ROIC	-124.38%	52W Low	0.61 394.27%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.56% 10.60%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.84%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.54	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	76.69	Recom	2.25
Dividend Gr. 3/5Y	- -	Current Ratio	10.54	EPS Q/Q	11.67%	SMA20	42.02%	Beta	2.97	Target Price	8.50
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	61.51%	Rel Volume	3.63	Prev Close	2.93
Employees	110	LT Debt/Eq	0.11	Earnings	Aug 06 AMC	SMA200	115.41%	Avg Volume	1.26M	Price	3.02
IPO	Sep 15, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.99% -	Trades		Volume	4,562,941	Change	3.07%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-27-25	Upgrade	Guggenheim	Neutral → Buy	$14
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform	$1
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Stifel	Buy → Hold	$6 → $2
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$29 → $4
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $15
Oct-01-24	Initiated	H.C. Wainwright	Buy	$30
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Show Previous Ratings

Oct-30-25 11:29PM	Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating (Insider Monkey) +17.20%
Oct-27-25 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 (GlobeNewswire)
06:30AM	Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model (GlobeNewswire)
Oct-01-25 07:00AM	Neumora Therapeutics to Host Virtual R&D Day on October 27 (GlobeNewswire)
Sep-17-25 09:40AM	Apple initiated, Hershey upgraded: Wall Streets top analyst calls (TipRanks)
09:35AM	Loading…
Sep-16-25 09:35AM	Apple initiated, Hershey upgraded: Wall Street's top analyst calls (The Fly)
Sep-02-25 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in September (GlobeNewswire)
Aug-20-25 12:13AM	Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861 (Insider Monkey)
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive) -11.52%
Aug-06-25 04:05PM	Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 10:23AM	Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating (Insider Monkey)
Jul-23-25 07:00AM	Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating (Insider Monkey)
Jul-09-25 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 (GlobeNewswire) +13.12%
May-13-25 03:10AM	Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ... (GuruFocus.com)
04:01PM	Loading…
May-12-25 04:01PM	Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:00AM	Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-22-25 02:49AM	Former Neumora CEO to lead Galapagos spinout (BioPharma Dive) +6.82%
Apr-21-25 04:10PM	Galapagos Announces Executive Leadership Updates (GlobeNewswire)
Mar-18-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Mar-07-25 12:26PM	J&J drops Phase III MDD programme due to lack of efficacy (Clinical Trials Arena)
07:08AM	J&J scraps depression testing for potential blockbuster drug (BioPharma Dive)
Mar-04-25 08:30AM	Neumora Therapeutics to Present at Leerink Global Healthcare Conference (GlobeNewswire)
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Mar-03-25 07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.94%
Feb-28-25 05:45AM	Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-26-25 08:46PM	Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-18-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-13-25 10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive)
07:00AM	Loading…
07:00AM	Neumora Therapeutics Announces Leadership Transition (GlobeNewswire)
Feb-11-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire) -6.18%
Jan-04-25 08:00AM	Neumora shares look oversold after 80% drop, says Mizuho (TipRanks)
Jan-03-25 07:20AM	Neumora Therapeutics navacaprant did not meet primary endpoint in depression (TipRanks) +10.15%
Jan-02-25 05:07PM	Results are in for a new depression drug trial, and they're cratering this stock (Quartz) -81.42%
04:22PM	Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops (Investor's Business Daily)
01:28PM	Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial (Insider Monkey)
01:07PM	Neumora shares sink following Phase III flop in MDD (Pharmaceutical Technology)
12:00PM	Top Stock Movers Now: Uber, Unity Software, Tesla, and More (Investopedia)
10:47AM	Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals (Investopedia)
09:59AM	Stock in Biotech Neumora Plunges 80% as Depression Drug Fails (Barrons.com)
09:54AM	Neumora Plunges After Major Depression Drug Fails in Study (Bloomberg)
08:30AM	Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials (Benzinga)
07:00AM	Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder (GlobeNewswire)
Nov-19-24 08:53AM	Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode (Insider Monkey)
Nov-12-24 07:00AM	Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -17.08%
Nov-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) +6.72%
Oct-29-24 07:00AM	Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Aug-14-24 07:00AM	Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders (GlobeNewswire)
Aug-06-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84% +6.73%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Oct 27 '25	Buy	2.61	1,915,700	4,999,977	6,046,907	Oct 29 07:22 PM
ARCH Venture Partners XII, LLC	10% Owner	Oct 27 '25	Buy	2.61	1,915,700	4,999,977	6,046,907	Oct 29 07:21 PM
ARCH Venture Partners X, LLC	10% Owner	Oct 27 '25	Buy	2.61	1,915,700	4,999,977	6,046,907	Oct 29 07:19 PM
Henry Gosebruch	Officer	Mar 12 '25	Proposed Sale	1.43	15,000	21,450		Mar 12 04:49 PM
BERNS PAUL L	See Remarks	Feb 18 '25	Sale	1.69	13,871	23,468	7,405,004	Feb 20 05:14 PM
Milligan Michael Lee	See Remarks	Feb 18 '25	Sale	1.69	1,978	3,351	22,470	Feb 20 05:14 PM
Aurora Daljit Singh	Chief Strategy Officer	Feb 18 '25	Sale	1.68	8,565	14,347	88,935	Feb 20 05:13 PM
Lenz Robert A.	Head of R&D	Feb 18 '25	Sale	1.67	5,614	9,383	309,092	Feb 20 05:12 PM
Pinto Joshua	President	Feb 18 '25	Sale	1.67	8,048	13,477	76,952	Feb 20 05:11 PM
Suh Carol Y.	Officer	Feb 18 '25	Proposed Sale	1.68	9,540	16,020		Feb 18 05:51 PM
Milligan Michael Lee	Officer	Feb 18 '25	Proposed Sale	1.69	1,978	3,351		Feb 18 05:49 PM
Pinto Joshua	Officer	Feb 18 '25	Proposed Sale	1.67	8,048	13,478		Feb 18 05:45 PM
Lenz Robert A.	Officer	Feb 18 '25	Proposed Sale	1.67	5,614	9,383		Feb 18 05:43 PM
Gosebruch Henry O	Officer	Feb 18 '25	Proposed Sale	1.67	6,857	11,462		Feb 18 05:41 PM
BERNS PAUL L	Officer	Feb 18 '25	Proposed Sale	1.69	13,871	23,468		Feb 18 05:40 PM
Aurora Daljit Singh	Officer	Feb 18 '25	Proposed Sale	1.68	8,565	14,348		Feb 18 05:38 PM

Open in Screener

SRRK

Scholar Rock Holding Corp

Oct 31 • 04:00PM ET

29.62

+0.25 0.85 %

Healthcare • Biotechnology • USA • NASD

SRRK Scholar Rock Holding Corp daily Stock Chart

Peers: VRTX REGN NBIX SRPT BMRN RARE FOLD IONS BLUE TVRD

| Held by: VTI XBI IWM VXF IWO VTWO IBB SCHA VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-3.02	Insider Own	22.50%	Shs Outstand	96.00M	Perf Week	-0.20%
Market Cap	2.85B	Forward P/E	-	EPS next Y	-2.74	Insider Trans	1.74%	Shs Float	74.50M	Perf Month	-15.83%
Enterprise Value	2.61B	PEG	-	EPS next Q	-0.84	Inst Own	100.79%	Short Float	22.71%	Perf Quarter	-19.92%
Income	-315.69M	P/S	-	EPS this Y	-33.77%	Inst Trans	3.37%	Short Ratio	6.62	Perf Half Y	-10.00%
Sales	0.00M	P/B	12.19	EPS next Y	17.14%	ROA	-111.37%	Short Interest	16.92M	Perf YTD	-31.47%
Book/sh	2.43	P/C	9.65	EPS next 5Y	11.97%	ROE	-172.08%	52W High	46.98 -36.95%	Perf Year	-4.24%
Cash/sh	3.07	P/FCF	-	EPS past 3/5Y	11.76% -5.90%	ROIC	-109.00%	52W Low	22.71 30.43%	Perf 3Y	270.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.23% 6.93%	Perf 5Y	115.89%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-29.50%	Oper. Margin	-	ATR (14)	2.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.88	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	6.33	EPS Q/Q	-61.56%	SMA20	-8.30%	Beta	0.81	Target Price	46.55
Payout	-	Debt/Eq	0.26	Sales Q/Q	-	SMA50	-10.55%	Rel Volume	0.62	Prev Close	29.37
Employees	196	LT Debt/Eq	0.24	Earnings	Nov 14 BMO	SMA200	-13.69%	Avg Volume	2.56M	Price	29.62
IPO	May 24, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-47.41% -	Trades		Volume	1,578,772	Change	0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-25	Initiated	BofA Securities	Buy	$53
Sep-17-25	Initiated	Barclays	Overweight	$45
Sep-15-25	Initiated	Leerink Partners	Outperform	$51
Aug-21-25	Resumed	Jefferies	Buy	$50
Jul-30-25	Resumed	Raymond James	Strong Buy	$53
Jul-17-25	Initiated	Cantor Fitzgerald	Overweight
Nov-26-24	Reiterated	H.C. Wainwright	Buy	$40 → $50
Oct-07-24	Reiterated	H.C. Wainwright	Buy	$30 → $35
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56
Apr-26-21	Resumed	Credit Suisse	Outperform	$65
Jan-11-21	Initiated	Credit Suisse	Outperform	$65
Jan-06-21	Initiated	JP Morgan	Overweight	$59
Mar-12-20	Initiated	Robert W. Baird	Outperform	$35

Show Previous Ratings

Oct-23-25 08:00AM	Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 (Business Wire)
Oct-17-25 06:15PM	Dayforce, Scholar Rock, and More Stocks See Action From Activist Investors (Barrons.com) -5.10%
04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Oct-13-25 05:22PM	Why Scholar Rock Stock Got Socked on Monday (Motley Fool) -13.14% -6.93%
05:07PM	Loading…
Oct-09-25 05:07PM	Why Scholar Rock Stock Raced 6% Higher Today (Motley Fool) +5.94%
Oct-08-25 01:10PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-23-25 04:06PM	Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback (Investor's Business Daily)
10:04AM	Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug (Investor's Business Daily)
07:11AM	US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall (Reuters)
07:00AM	FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility (Business Wire)
06:19AM	Scholar Rock SMA drug rejected by FDA over manufacturing concerns (BioPharma Dive)
Sep-15-25 04:54PM	Why Scholar Rock Stock Bounced Higher on Monday (Motley Fool) +6.32%
Sep-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 03:31AM	Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger? (Insider Monkey)
12:18PM	Loading…
Aug-21-25 12:18PM	Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD (Insider Monkey)
Aug-15-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:20AM	Veru Announces Novel Modified-Release Oral Formulation for Enobosarm (Zacks)
Aug-14-25 08:00AM	Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment (Business Wire)
Aug-11-25 08:21PM	Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss (Insider Monkey)
Aug-06-25 05:10PM	Why Scholar Rock Stock Wilted on Wednesday (Motley Fool) -6.40% -9.30%
07:00AM	Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
Jul-21-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 (Business Wire)
Jul-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-23-25 08:00AM	Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial (Business Wire)
Jun-20-25 03:45PM	Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says (Reuters) -6.28%
Jun-19-25 02:01PM	Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial (Insider Monkey)
Jun-18-25 01:41PM	Why Scholar Rock Shares Are Soaring Today (Motley Fool) +16.60%
11:40AM	Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results (Investopedia)
07:42AM	Scholar Rock drug preserves muscle in obesity trial (BioPharma Dive)
07:00AM	Loading…
07:00AM	Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss (Business Wire)
Jun-13-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 08:00AM	Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire) +11.13%
Jun-02-25 08:00AM	Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager (Business Wire)
May-28-25 08:00AM	Scholar Rock to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.28%
May-16-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-25 03:10AM	Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ... (GuruFocus.com)
01:39AM	Q1 2025 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:00AM	Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
May-13-25 09:24AM	What To Expect From Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings (GuruFocus.com)
May-07-25 08:00AM	Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 (Business Wire)
May-06-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.01%
Apr-28-25 07:08PM	Why Scholar Rock Stock Took a Knock on Monday (Motley Fool)
06:50AM	Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth (Business Wire)
Apr-23-25 06:34PM	Why Scholar Rock Holding Stock Topped the Market Today (Motley Fool) +5.72%
Apr-21-25 04:37PM	Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ... (GuruFocus.com) +6.14%
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-25-25 07:30AM	FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy (Business Wire)
Mar-17-25 08:31AM	Scholar Rock SMA drug shows muscle function benefit (Clinical Trials Arena)
Mar-16-25 07:00PM	Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
Mar-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 11:16PM	Q4 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents) +7.95%
07:00AM	Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress (Business Wire)
Feb-26-25 07:24AM	Earnings To Watch: Scholar Rock Holding Corp (SRRK) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 04:15PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-25 01:10PM	Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now? (Insider Monkey)
Feb-21-25 08:00AM	Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Feb-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-10-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025 (Business Wire)
Jan-29-25 08:05AM	Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
08:00AM	Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition (Business Wire)
Jan-17-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-13-25 06:48PM	Heres Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing (Insider Monkey) +5.21%
Jan-08-25 04:00PM	Scholar Rock Highlights 2025 Strategic Priorities (Business Wire)
Jan-02-25 08:00AM	Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-04-24 12:36PM	Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga) +26.07%
06:13AM	Biohaven muscle drug misses goal of SMA study, but advances in obesity (BioPharma Dive)
Nov-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 02:08AM	Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 07:00AM	Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress (Business Wire) -5.29%
Nov-11-24 07:07AM	Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 08:00AM	Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin (Business Wire)
Nov-01-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (Business Wire)
Oct-31-24 04:00PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire) -5.14%
08:00AM	Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting (Business Wire)
Oct-22-24 08:00AM	Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering (Business Wire)
Oct-21-24 09:55AM	Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? (Zacks)
Oct-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-11-24 06:30PM	PBF Energy, Gold Reserve, and More Stocks See Action From Activist Investors (Barrons.com) +7.58%
Oct-09-24 05:34PM	Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ... (GuruFocus.com) -5.83% -5.87%
05:38AM	Here's Why Everybody's Talking About Scholar Rock Right Now (Motley Fool)
Oct-08-24 11:08PM	Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -13.97%
08:29AM	Scholar Rocks SMA Treatment Trials Show Promising Results (TipRanks)
06:43AM	Scholar Rock stocks skyrocket after SMA drug scores at Phase III (Clinical Trials Arena)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +361.99%
04:09PM	Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
03:23PM	Scholar Rock Shares Quadruple On Positive Drug-Study Results (The Wall Street Journal)
11:05AM	Scholar Rock stock surges on positive spinal muscular atrophy treatment data (Investing.com)
11:05AM	Scholar Rock Stock Quadruples on Positive Trial Data (Barrons.com)
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
07:00AM	Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
Sep-27-24 06:13AM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now (Insider Monkey)
Sep-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.48%
Sep-10-24 08:00AM	Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity (Business Wire) +5.89%

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	Oct 03 '25	Buy	37.27	387,414	14,438,544	387,414	Oct 07 08:59 PM
AKKARAJU SRINIVAS	Director	Oct 06 '25	Buy	38.65	113,025	4,368,808	500,439	Oct 07 08:59 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 22 '25	Sale	30.67	3,353	102,846	108,964	Sep 24 04:30 PM
Mohammed Qatanani	Officer	Sep 22 '25	Proposed Sale	30.67	3,353	102,846		Sep 22 04:33 PM
Peng Katie	Director	Sep 16 '25	Sale	32.53	1,006	32,726	33,914	Sep 17 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 16 '25	Sale	33.52	3,178	106,527	112,317	Sep 17 04:30 PM
Katie Peng	Director	Sep 16 '25	Proposed Sale	32.53	1,006	32,726		Sep 16 04:32 PM
Parlavecchio Caryn	CHRO	Aug 18 '25	Sale	31.17	2,178	67,880	155,464	Aug 19 04:30 PM
FLIER JEFFREY S.	Director	Jul 16 '25	Sale	40.02	11,136	445,688	0	Jul 18 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jul 08 '25	Sale	34.44	24,066	828,898	115,495	Jul 10 09:46 PM
Mohammed Qatanani	Officer	Jul 08 '25	Proposed Sale	35.48	24,066	853,862		Jul 08 04:12 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Option Exercise	21.62	20,316	439,232	44,386	Jun 25 04:30 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Sale	32.24	20,316	654,904	24,070	Jun 25 04:30 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Sale	33.21	11,136	369,818	11,136	Jun 25 04:30 PM
Peng Katie	Director	Jun 16 '25	Sale	31.97	3,031	96,888	34,920	Jun 17 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jun 16 '25	Sale	32.00	3,668	117,381	139,561	Jun 17 04:30 PM
Parlavecchio Caryn	CHRO	Jun 16 '25	Sale	32.00	6,186	197,961	157,642	Jun 17 04:30 PM
Ho Junlin	GENERAL COUNSEL	Jun 16 '25	Sale	32.00	7,442	238,154	222,569	Jun 17 04:30 PM
Edward Myles	Former Officer	Jun 05 '25	Proposed Sale	32.50	19,599	636,967		Jun 05 04:57 PM
FLIER JEFFREY S.	Director	May 29 '25	Sale	29.73	6,075	180,584	24,070	May 30 04:32 PM
Burow Kristina	Director	May 29 '25	Sale	29.72	5,400	160,511	21,071	May 30 04:31 PM
Gilman Michael	Director	May 29 '25	Sale	29.72	3,375	100,304	55,216	May 30 04:31 PM
Brudnick Richard	Director	May 29 '25	Sale	29.72	6,075	180,531	15,057	May 30 04:31 PM
Reed Joshua	Director	May 29 '25	Sale	29.72	5,400	160,463	15,732	May 30 04:30 PM
Vaishnaw Akshay	President of R&D	May 29 '25	Sale	29.72	6,750	200,612	616,205	May 30 04:30 PM
Akshay Vaishnaw	Director	May 29 '25	Proposed Sale	29.66	6,750	200,205		May 29 04:51 PM
Joshua Reed	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:49 PM
Michael Gilman	Director	May 29 '25	Proposed Sale	29.66	3,375	100,103		May 29 04:46 PM
Jeffrey S. Flier	Director	May 29 '25	Proposed Sale	29.66	48,663	1,443,345		May 29 04:43 PM
Kristina Burow	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:39 PM
Richard Brudnick	Director	May 29 '25	Proposed Sale	29.66	6,075	180,185		May 29 04:35 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Option Exercise	10.00	5,000	50,000	76,250	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Sale	32.83	5,000	164,131	71,750	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Option Exercise	10.00	5,000	50,000	78,250	Mar 25 07:39 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Sale	33.08	6,500	215,014	71,750	Mar 25 07:39 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Option Exercise	17.33	13,564	235,085	96,173	Mar 25 07:37 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Sale	33.12	13,564	449,237	82,609	Mar 25 07:37 PM
Tracey Sacco	Affiliate	Mar 24 '25	Proposed Sale	33.00	41,500	1,369,500		Mar 24 07:20 PM
Peng Katie	Director	Mar 17 '25	Sale	34.42	1,006	34,627	30,319	Mar 19 05:00 PM
Katie Peng	Director	Mar 17 '25	Proposed Sale	34.60	4,037	139,680		Mar 17 06:50 PM
Myles Edward H	COO & CFO	Mar 10 '25	Option Exercise	13.60	112,897	1,535,083	253,637	Mar 12 07:06 PM
Myles Edward H	COO & CFO	Mar 10 '25	Sale	35.62	142,292	5,068,974	111,345	Mar 12 07:06 PM
Edward Myles	Officer	Mar 10 '25	Proposed Sale	35.00	161,890	5,666,150		Mar 10 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Option Exercise	10.19	48,308	492,186	179,594	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Sale	37.40	68,510	2,562,479	111,084	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	36.83	4,135	152,288	131,286	Feb 20 07:55 PM
Parlavecchio Caryn	CHRO	Feb 18 '25	Sale	36.83	5,296	195,046	140,258	Feb 20 06:30 PM
Myles Edward H	COO & CFO	Feb 18 '25	Sale	36.83	7,809	287,598	140,740	Feb 20 06:18 PM
Ho Junlin	GENERAL COUNSEL	Feb 18 '25	Sale	36.83	5,742	211,472	189,295	Feb 20 05:53 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	36.83	18,372	676,622	311,991	Feb 20 05:41 PM
Mohammed Qatanani	Officer	Feb 19 '25	Proposed Sale	36.95	68,510	2,531,444		Feb 19 04:15 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Jan 16 '25	Sale	44.20	22,308	985,951	330,363	Jan 21 04:35 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Jan 16 '25	Sale	44.20	5,655	249,935	67,200	Jan 21 04:35 PM
Sacco Tracey	Chief Commercial Officer	Jan 16 '25	Sale	44.20	3,890	171,927	45,395	Jan 21 04:35 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 16 '25	Sale	44.20	7,347	324,717	135,421	Jan 21 04:35 PM
Parlavecchio Caryn	CHRO	Jan 16 '25	Sale	44.20	6,434	284,365	145,554	Jan 21 04:35 PM
Myles Edward H	COO & CFO	Jan 16 '25	Sale	44.20	12,539	554,189	148,549	Jan 21 04:35 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '25	Sale	44.20	9,039	399,498	195,037	Jan 21 04:35 PM
Invus Public Equities, L.P.	10% Owner	Dec 10 '24	Sale	41.65	1,600,000	66,640,000	9,250,005	Dec 12 04:39 PM
Invus Public Equities, L.P.	10% Owner	Nov 25 '24	Sale	38.49	409,433	15,757,639	10,850,005	Nov 27 04:31 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Option Exercise	8.59	6,375	54,761	79,230	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Option Exercise	8.59	2,145	18,426	75,000	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Sale	39.44	6,375	251,399	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Sale	30.01	2,145	64,372	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Option Exercise	8.59	2,105	18,082	74,960	Nov 13 04:40 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Sale	30.00	2,105	63,158	72,855	Nov 13 04:40 PM

Open in Screener

MTSR

Metsera Inc

Oct 31 • 04:00PM ET

63.04

-0.69 -1.08 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI XBI IWM VB VBK VXF SCHA IWO VTWO IWN

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	54.41%	Shs Outstand	104.89M	Perf Week	20.05%
Market Cap	6.64B	Forward P/E	-	EPS next Y	-3.60	Insider Trans	-0.00%	Shs Float	48.00M	Perf Month	21.93%
Enterprise Value	6.11B	PEG	-	EPS next Q	-0.72	Inst Own	30.33%	Short Float	10.15%	Perf Quarter	83.04%
Income	-	P/S	-	EPS this Y	79.23%	Inst Trans	5.25%	Short Ratio	2.26	Perf Half Y	145.77%
Sales	-	P/B	14.72	EPS next Y	-19.60%	ROA	-	Short Interest	4.87M	Perf YTD	137.89%
Book/sh	4.28	P/C	12.50	EPS next 5Y	32.84%	ROE	-	52W High	66.10 -4.63%	Perf Year	-
Cash/sh	5.04	P/FCF	-	EPS past 3/5Y	-1497.55% -	ROIC	-	52W Low	12.30 412.52%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.39% 1.19%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.88	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.26	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	83.15	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.26	EPS Q/Q	-239.61%	SMA20	17.26%	Beta	-	Target Price	57.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	37.15%	Rel Volume	2.79	Prev Close	63.73
Employees	81	LT Debt/Eq	0.00	Earnings	Jul 28 AMC	SMA200	90.28%	Avg Volume	2.15M	Price	63.04
IPO	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.29% -	Trades		Volume	5,999,158	Change	-1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$54
Sep-09-25	Initiated	Leerink Partners	Outperform	$77
Jun-20-25	Initiated	Wells Fargo	Overweight	$65
Feb-25-25	Initiated	Guggenheim	Buy	$56
Feb-25-25	Initiated	Evercore ISI	Outperform
Feb-25-25	Initiated	BofA Securities	Buy	$38

Oct-31-25 05:12PM	Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal (The Wall Street Journal)
06:24PM	Metsera Issues Statement in Response to Litigation (PR Newswire)
05:28PM	Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk (Associated Press Finance)
05:30PM	Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal (Investor's Business Daily)
03:50PM	Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition (Business Wire)
12:36PM	Loading…
12:36PM	Health Care Roundup: Market Talk (The Wall Street Journal)
11:07AM	Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results? (Zacks)
10:28AM	Novo Nordisk cuts 9,000 jobs as it looks to new weight-loss drugs (Reuters Videos)
10:03AM	Metsera (MTSR) Soars to All-Time High on Pfizer, Novo Billion-Dollar Bidding War (Insider Monkey)
08:03AM	Massive sales for weight loss drugs spur Eli Lillys Q3 (Pharmaceutical Technology)
05:50AM	Bull market not solely driven by AI. M&A is starting to heat up. (MarketWatch)
Oct-30-25 06:53PM	Mizuho's Holtz talks what is behind Novo's bid for Metsera (CNBC TV) +22.06%
04:47PM	These Stocks Moved the Most Today: Meta, Microsoft, Alphabet, FMC, C.H. Robinson Worldwide, Roblox, Metsera, Chipotle, and More (Barrons.com)
04:35PM	Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle (The Wall Street Journal)
03:03PM	Novo Nordisk takes on Pfizer in bid for obesity biotech Metsera (Reuters Videos)
02:16PM	Loading…
02:16PM	Pfizer said to mull suing Novo Nordisk over Metsera bid (Investing.com)
02:11PM	Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. (Barrons.com)
02:10PM	These Stocks Are Moving the Most Today: Meta, Microsoft, Alphabet, FMC, C.H. Robinson Worldwide, Roblox, Metsera, Chipotle, and More (Barrons.com)
01:31PM	Bidding war rises over weight loss drug that could prevent Ozempic face (The Telegraph)
01:19PM	Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera (Investor's Business Daily)
01:11PM	Chipotle drags fast casual stocks lower, Meta reports raising $125B (Yahoo Finance Video)
12:52PM	Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera (The Wall Street Journal)
12:27PM	Halper Sadeh LLC Encourages GES, MTSR, TGNA, CYBR Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
11:23AM	Novo Nordisk locks horns with Pfizer in late bid for Metsera (Pharmaceutical Technology)
10:41AM	Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Chipotle (The Wall Street Journal)
10:39AM	Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war (Associated Press Finance)
10:04AM	Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle (Bloomberg)
09:25AM	Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook (Yahoo Finance Video)
09:13AM	Novo Nodrisk stock dips on aggressive odder to buy Metsera, reckless says Pfizer (Investing.com)
08:20AM	Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera (AFP)
07:57AM	Loading…
07:57AM	Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings (The Wall Street Journal)
07:11AM	Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker. (Barrons.com)
07:07AM	Metsera Receives Unsolicited Proposal from Novo Nordisk (PR Newswire)
06:57AM	Pfizer Addresses Proposal for Metsera (Business Wire)
06:32AM	Pfizer and Roche place $10bn bets on obesity and liver disease therapies as Trump tightens grip on drug pricing and manufacturing (Pharmaceutical Technology)
06:23AM	Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera (The Wall Street Journal)
Oct-27-25 06:24AM	Google Parent Alphabet Has $754 Million Invested in These 3 Hot Growth Stocks. Here's the 1 Wall Street Likes the Most. (Motley Fool)
Oct-13-25 08:45AM	Where Will Pfizer Be in 5 Years? (Motley Fool)
05:30AM	Why Biotech's Rally Can Last This Time (The Wall Street Journal)
Oct-07-25 09:30AM	Down 50%, Should You Buy the Dip on Pfizer? (Motley Fool)
Oct-06-25 04:59AM	3 Reasons to Buy Pfizer Stock Now (Motley Fool)
Oct-02-25 07:02AM	3 Things You Need to Know if You Buy Pfizer Today (Motley Fool)
Sep-30-25 11:02AM	Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer. (Barrons.com)
07:50AM	Metsera strengthens case for Pfizer buyout with latest study data (BioPharma Dive)
04:00AM	Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out (Motley Fool)
Sep-29-25 04:01PM	Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 (GlobeNewswire)
Sep-28-25 10:58AM	Down 55%, Should You Buy the Dip on Pfizer? (Motley Fool)
Sep-27-25 08:15AM	Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet? (Motley Fool)
Sep-26-25 04:33PM	Pfizer is Locking in New Growth Through a New Acquisition (MarketBeat)
08:45AM	Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock? (Motley Fool)
Sep-25-25 09:35AM	Metsera downgraded to Market Perform from Outperform at Leerink (TipRanks)
04:00AM	Can a multibillion-dollar deal put Pfizer in the obesity big leagues? (Pharma Voice)
Sep-23-25 06:55PM	Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock? (Zacks)
02:13PM	Metsera (MTSR) Soars to All-Time High on $7.3-Billion Merger With Pfizer (Insider Monkey)
12:16PM	Can PFE Successfully Return to the Obesity Space With Metsera Buyout? (Zacks)
05:30AM	This Hated Stock Suddenly Looks Like an Obesity Bargain (The Wall Street Journal)
04:35AM	Company News for Sep 23, 2025 (Zacks)
03:47AM	What's Pfizer Getting in Its $7.3 Billion Metsera Buyout? (Motley Fool)
02:41AM	Heard on the Street Tuesday Recap: Even Tylenol Cant Cool This AI Fever (The Wall Street Journal)
Sep-22-25 11:49PM	Asian shares trade mixed after US stocks set more records (Associated Press Finance) +60.80%
09:41PM	Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles (TheStreet)
06:00PM	Podcast: Nasdaq Leads U.S. Stocks to New Records (The Wall Street Journal)
04:20PM	Stocks to Watch Recap: Nvidia, Oracle, Pfizer, Kenvue, Compass (The Wall Street Journal)
04:12PM	These Stocks Moved the Most Today: Oracle, Nvidia, Metsera, Pfizer, Kenvue, Tesla, Anywhere Real Estate, and More (Barrons.com)
02:53PM	These Stocks Are Moving the Most Today: Oracle, Nvidia, Metsera, Pfizer, Kenvue, Tesla, Anywhere Real Estate, and More (Barrons.com)
01:50PM	Stocks to Watch Monday: Nvidia, Oracle, Pfizer, Kenvue, Compass (The Wall Street Journal)
01:28PM	Why Pfizer Stock Just Popped (Motley Fool)
12:51PM	Pfizer Joins Obesity Drug Race With $5B Metsera Purchase (Bloomberg)
12:26PM	Pfizer buys monthly GLP-1RA developer Metsera for $4.9bn (Pharmaceutical Technology)
11:17AM	Pfizer Jumps Back into the Weight-Loss Race With $4.9B Acquisition (Barrons.com)
11:08AM	Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout (Schaeffer's Research)
10:37AM	Stock Market Today: Dow Up As Apple, Tesla Gain On These Calls; Oracle Pops After Executive Shuffle (Live Coverage) (Investor's Business Daily)
10:37AM	Stock Market Today: Dow Falls As Apple, Tesla Gain On These Calls; Obesity Play Rockets On Pfizer Move (Live Coverage) (Investor's Business Daily)
09:56AM	Pfizer eyes obesity drug market as it seals $4.9bn deal for Metsera (Euronews)
09:41AM	Stocks to Watch Monday: Oracle, Pfizer, Fox, Compass (The Wall Street Journal)
09:31AM	Oracle, Pfizer & Metsera, Kenvue: Trending tickers (Yahoo Finance Video)
09:11AM	Pfizer Claws Deeper Into The Obesity Space With $4.9 Billion Metsera Deal (Investor's Business Daily)
08:57AM	Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal (Investopedia)
08:54AM	Pfizer to acquire Metsera: Breaking News (Yahoo Finance Video)
08:26AM	5 Things to Know Before the Stock Market Opens (Investopedia)
08:14AM	Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal (MarketWatch)
07:44AM	Pfizer amps up push into obesity treatments with $4.9B deal for Metsera (Associated Press Finance)
07:42AM	This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer (Barrons.com)
07:32AM	Pfizer seals up to $7.3bn takeover of weight loss drugmaker Metsera (Financial Times)
07:06AM	Stocks to Watch Monday: Fox, Compass, Infosys, Metsera (The Wall Street Journal)
07:02AM	Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion (The Wall Street Journal)
06:45AM	Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio (Business Wire)
06:40AM	Coinbase drops with cryptos under pressure and more stocks on the move (MarketWatch)
06:03AM	These Stocks Are Moving the Most Today: Fox, Coinbase, Metsera, Pfizer, Kenvue, Tesla, and More (Barrons.com)
03:49AM	Stock Market Today: Dow, S&P 500 and Nasdaq set to retreat as gold vaults to new high (MarketWatch)
12:04AM	Pfizer to buy weight-loss drug developer Metsera in $7.3 billion deal (Reuters)
Sep-11-25 11:14AM	Metsera, Inc. (MTSR)'s MET-233i Shows 8% Weight Loss in Phase 1 (Insider Monkey)
07:00AM	Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting (GlobeNewswire)
Sep-10-25 12:59AM	Bank of America Securities Raises PT on Metsera (MTSR), Keeps a Buy (Insider Monkey)
Aug-27-25 04:01PM	Metsera to Present at Upcoming September Investor Conferences (GlobeNewswire) +5.51%
Aug-20-25 12:14AM	Metsera's (MTSR) Amylin Agonist Data Leads to Price Target Increase (Insider Monkey)
Jul-28-25 04:01PM	Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress (GlobeNewswire) -5.73%
08:50AM	Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why (Zacks)
Jul-14-25 07:52AM	Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association (Insider Monkey) +8.12%
Jul-10-25 09:55AM	Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? (Zacks)

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FMR LLC	See Remark 1	Sep 02 '25	Sale	36.00	268	9,648	0	Sep 04 02:58 PM
Burow Kristina	Director	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:15 PM
BERNS PAUL L	Director	Feb 03 '25	Buy	18.00	789,998	14,219,964	8,313,680	Feb 03 07:04 PM
ARCH Venture Partners XII, LLC	10% Owner	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:01 PM

Open in Screener

BOLD

Boundless Bio Inc

Oct 31 • 04:00PM ET

1.40

+0.02 1.45 %

Healthcare • Biotechnology • USA • NASD

BOLD Boundless Bio Inc daily Stock Chart

Peers: BLUE NTLA CRSP EDIT SGMO BNGO CERS MESO FATE CLLS

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-2.89	Insider Own	29.03%	Shs Outstand	22.39M	Perf Week	-4.11%
Market Cap	31.34M	Forward P/E	-	EPS next Y	-2.43	Insider Trans	0.00%	Shs Float	15.89M	Perf Month	15.70%
Enterprise Value	-46.30M	PEG	-	EPS next Q	-0.58	Inst Own	38.24%	Short Float	0.86%	Perf Quarter	16.67%
Income	-64.39M	P/S	-	EPS this Y	34.55%	Inst Trans	-13.24%	Short Ratio	1.18	Perf Half Y	-12.77%
Sales	0.00M	P/B	0.26	EPS next Y	3.57%	ROA	-35.03%	Short Interest	0.14M	Perf YTD	-51.72%
Book/sh	5.48	P/C	0.25	EPS next 5Y	35.36%	ROE	-42.65%	52W High	3.75 -62.67%	Perf Year	-55.27%
Cash/sh	5.68	P/FCF	-	EPS past 3/5Y	-50.29% -	ROIC	-37.82%	52W Low	1.00 40.00%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.82% 6.14%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-10.95%	Oper. Margin	-	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.08	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.11	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	14.08	EPS Q/Q	9.03%	SMA20	1.93%	Beta	-0.12	Target Price	3.50
Payout	-	Debt/Eq	0.40	Sales Q/Q	-	SMA50	12.62%	Rel Volume	0.99	Prev Close	1.38
Employees	64	LT Debt/Eq	0.39	Earnings	Aug 05 BMO	SMA200	-3.13%	Avg Volume	115.24K	Price	1.40
IPO	Mar 28, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-7.69% -	Trades		Volume	114,517	Change	1.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Initiated	H.C. Wainwright	Buy	$5
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform	$3
Dec-13-24	Downgrade	Guggenheim	Buy → Neutral
Apr-22-24	Initiated	Piper Sandler	Overweight	$20
Apr-22-24	Initiated	Leerink Partners	Outperform	$25
Apr-22-24	Initiated	Guggenheim	Buy	$24

Oct-13-25 04:05PM	Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-05-25 07:00AM	Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Jun-05-25 04:58PM	Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-23-25 04:01PM	Boundless Bio Announces Portfolio Prioritization and Runway Extension (GlobeNewswire) -15.58%
May-14-25 12:00PM	Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know (Zacks)
07:00AM	Loading…
May-09-25 07:00AM	Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-01-25 08:23AM	New Strong Sell Stocks for May 1st (Zacks) -8.52%
Apr-03-25 07:00AM	Boundless Bio to Participate in the Needham Virtual Healthcare Conference (GlobeNewswire) -7.38%
Mar-27-25 07:00AM	Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire)
Feb-26-25 07:00AM	Boundless Bio to Participate in the Leerink Global Healthcare Conference (GlobeNewswire)
Feb-03-25 10:00AM	Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Dec-12-24 04:01PM	Boundless Bio Announces Pipeline and Leadership Updates (GlobeNewswire) -12.72% -16.61%
Nov-25-24 07:00AM	Boundless Bio to Participate in the Piper Sandler Healthcare Conference (GlobeNewswire) +8.94%
Nov-07-24 04:01PM	Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +5.42%
Nov-05-24 07:00AM	Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Oct-14-24 08:00AM	Boundless Bio Announces Departure of Chief Financial Officer (GlobeNewswire)
Sep-11-24 07:00AM	Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-13-24 04:28AM	Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO (FierceBiotech.com)
03:32AM	Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now? (Insider Monkey)
Aug-12-24 10:53PM	BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024 (InvestorPlace) -6.19%
04:01PM	Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-05-24 07:00AM	Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-13-24 02:53PM	BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024 (InvestorPlace) +10.83%
07:00AM	Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights (Business Wire)
May-06-24 08:00AM	Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 (Business Wire)
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire)
Apr-14-24 11:37AM	Insiders are Amassing These 10 Stocks in April (Insider Monkey)
Apr-11-24 08:00AM	Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications (Business Wire)
Apr-08-24 08:00AM	Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 (Business Wire) -5.75%
Mar-27-24 06:55PM	Boundless Bio Announces Pricing of Initial Public Offering (Business Wire)

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.

NMRA

Neumora Therapeutics Inc

SRRK

Scholar Rock Holding Corp

MTSR

Metsera Inc

BOLD

Boundless Bio Inc

Upgrade your FINVIZ experience